Minerva Neurosciences Reports Positive Phase 1 Data With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia

Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen.

WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV ) today announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. The three Phase 1 studies were conducted by Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, as part of a collaboration to develop MIN-202 with Minerva that was facilitated by Johnson & Johnson Innovation Ltd in London.

"Treatment of sleep disorders remains a significant challenge in patients with both primary insomnia and many CNS diseases. These positive data indicate that MIN-202 could be an effective treatment able to both induce and maintain sleep," said Remy Luthringer, PhD, president and CEO of Minerva, adding "With these findings we have identified a dose range to advance this compound."

In patients with mood disorders, sleep disturbances (both insomnia and hypersomnia) have been associated with a suboptimal response to antidepressant drug (AD) therapy, an increased risk for relapse (in AD-responsive patients), and prodromal depression. Recent studies have shown that orexin-2 receptor antagonism might have a beneficial effect on overall arousal and stress level.

"We are especially encouraged by findings that support the use of MIN-202 in the treatment of both primary insomnia as well as sleep disorders associated with MDD," Dr. Luthringer added.

MIN-202 Phase 1b Study in MDD Patients

This was a double-blind, placebo-controlled, randomized, four-way crossover, single dose study in 20 male and female patients with MDD and insomnia. The primary endpoint was the effect of MIN-202 (dosed PM) on latency to persistent sleep (LPS). Some additional endpoints were evaluated by PSG (polysomnography). Preliminary results demonstrated a statistically significant effect on LPS in all three doses tested (10, 20, and 40 mg). Treatment with MIN-202 also resulted in prolonged total sleep duration by approximately 45 minutes.

MIN-202 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers

This was a double-blind, placebo-controlled, randomized MAD study in sequential cohorts of healthy males and females. MIN-202 was administered in the morning at dose levels ranging from 5mg to 60mg for 10 days. A dose level as low as 5mg was shown to elicit sedation while dose levels ≥ 20mg induced (daytime) somnolence. MIN-202 plasma exposure was dose proportional from 5mg to 20mg. At higher doses, the exposure was less than dose proportional.

MIN-202 Phase 1 Bio-Availability (BA) Study

The two studies described above were carried out using a suspension formulation of MIN-202. This third study evaluated treatment with a solid dose formulation of MIN-202 to potentially support additional clinical studies. In this study, similar pharmacokinetic profiles were observed for both formulations, qualifying the solid dose to support further clinical studies. 

In these Phase 1 studies, MIN-202 was found to be generally well tolerated. 

About MIN-202

MIN-202 is an orexin-2 (OX) antagonist being developed by Minerva Neurosciences in collaboration with Janssen Pharmaceutica NV, for the treatment of sleep disorders. The most commonly available medications to treat insomnia are GABA-mimetics (e.g., Ambien), which activate sleep-promoting neurons.  During the last decade, the critical role of the orexin system in maintaining wakefulness in humans has been confirmed.  Promoting sleep by inhibiting the OX-2 receptor may hold the promise of improved safety (decreased interactions with other CNS functions), better restoration of natural sleep architecture (structure and pattern of sleep), and improved continuity (amount and distribution of sleep versus wakefulness), potentially leading to improvements in sleep quality and next day functioning.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Minerva is developing first-in-class proprietary compounds, including its lead program MIN-101 in Phase IIb development for the treatment of schizophrenia, MIN-202 in Phase I development for primary and comorbid insomnia, MIN-301, which is in preclinical development for the treatment of Parkinson's disease, and MIN-117 targeting major depressive disorder. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV". For more information, please visit: www.minervaneurosciences.com/ .

Forward-Looking Safe-Harbor Statement:

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect the timing and results of future clinical milestones; the timing of future clinical trials and results of clinical trials regarding MIN-202; clinical and therapeutic potential of MIN-202; our ability to successfully develop and commercialize MIN-202; and management's ability to successfully achieve its goals. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors including, without limitation, whether the final results of the three MIN-202 Phase 1 studies will differ materially from the preliminary results; whether MIN-202 or any of our other therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether MIN-202 and our other therapeutic products will be successfully marketed if approved; whether any of our other therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 6, 2014. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Media Contact: Bill Berry Berry & Company Public Relations Tel: 212-253-8881 Investor Contact: Renee Leck Stern Investor Relations Tel: 212-362-1200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 94

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 13

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 156

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 69

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 205

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Centene Investors on Class Action Case

Updated Category News Views 125

Overview of the Class Action Lawsuit Against Centene A critical reminder has emerged for investors of Centene Corporation regarding the ongoing class action lawsuit. The litigation is focused on allegations that may involve significant losses for shareholders, particularly those whose financial stakes in the company have been adversely affected. Lead Plaintiff Deadline...

Continue Reading
Keith Gabel and Sercomm to Unveil Innovations at SCTE TechExpo

Updated Category News Views 299

Keith Gabel to Join Sercomm at SCTE TechExpo for Product Launch Sercomm, a renowned provider in the telecom and broadband sector, is set to make waves at the upcoming SCTE TechExpo. The company is excited to announce that U.S. Paralympic and World Champion snowboarder, Keith Gabel, will be a special guest during this significant event. This collaboration spotlights not...

Continue Reading
Crafting a Small Biz Site That Converts Consistently

Updated Category News Views 28

Making an Impression: Small Biz Website Must-Haves First impressions aren't just for dinner parties or nervous job interviews. They're the bread and butter of small business websites, and if you flub it, your visitors are gone before you can blink. Sean O'Kelly, a digital marketing whiz, throws down some knowledge in HelloNation, drilling into what makes a small business...

Continue Reading
Cooper Standard Launches Innovative FlexiCore Thermoplastic Seal

Updated Category News Views 88

Revolutionizing Automotive Sealing Solutions Cooper Standard, a premier global supplier in sealing and fluid handling, is once again leading the industry with the introduction of the FlexiCore™ Thermoplastic Body Seal. This innovative product represents a significant leap in automotive sealing technology, aiming to provide a more sustainable, lightweight, and efficient...

Continue Reading
Coupang Securities Class Action: Investors' Rights Explained

Updated Category News Views 166

Coupang Securities Class Action Overview In the world of investments, staying informed is crucial, especially when facing legal challenges. The case involving Coupang, Inc. has drawn significant attention recently, primarily due to allegations of securities fraud linked to a data breach and subsequent stock decline. This case emphasizes the importance of understanding how...

Continue Reading